Literature DB >> 7617529

Neural network predicted peak and trough gentamicin concentrations.

M E Brier1, J M Zurada, G R Aronoff.   

Abstract

Predictions of steady state peak and trough serum gentamicin concentrations were compared between a traditional population kinetic method using the computer program NONMEM to an empirical approach using neural networks. Predictions were made in 111 patients with peak concentrations between 2.5 and 6.0 micrograms/ml using the patient factors age, height, weight, dose, dose interval, body surface area, serum creatinine, and creatinine clearance. Predictions were also made on 33 observations that were outside the 2.5 and 6.0 micrograms/ml range. Neural networks made peak serum concentration predictions within the 2.5-6.0 micrograms/ml range with statistically less bias and comparable precision with paired NONMEM predictions. Trough serum concentration predictions were similar using both neural networks and NONMEM. The prediction error for peak serum concentrations averaged 16.5% for the neural networks and 18.6% for NONMEM. Average prediction errors for serum trough concentrations were 48.3% for neural networks and 59.0% for NONMEM. NONMEM provided numerically more precise and less biased predictions when extrapolating outside the 2.5 and 6.0 micrograms/ml range. The observed peak serum concentration distribution was multimodal and the neural network reproduced this distribution with less difference between the actual distribution and the predicted distribution than NONMEM. It is concluded that neural networks can predict serum drug concentrations of gentamicin. Neural networks may be useful in predicting the clinical pharmacokinetics of drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617529     DOI: 10.1023/a:1016260720218

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

2.  Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model.

Authors:  P D Jensen; B E Edgren; R C Brundage
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

3.  Application of neural computing in pharmaceutical product development.

Authors:  A S Hussain; X Q Yu; R D Johnson
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

4.  Population pharmacokinetics of gentamicin in neonates.

Authors:  A H Thomson; S Way; S M Bryson; E M McGovern; A W Kelman; B Whiting
Journal:  Dev Pharmacol Ther       Date:  1988

5.  Application of neural networks to pharmacodynamics.

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharm Sci       Date:  1993-09       Impact factor: 3.534

Review 6.  Trends in clinical pharmacokinetics.

Authors:  M M Reidenberg
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

7.  Feasibility of developing a neural network for prediction of human pharmacokinetic parameters from animal data.

Authors:  A S Hussain; R D Johnson; N N Vachharajani; W A Ritschel
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

8.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation.

Authors:  P Cohen; L Collart; C G Prober; A F Fischer; T F Blaschke
Journal:  Pediatr Infect Dis J       Date:  1990-08       Impact factor: 2.129

10.  Estimation of gentamicin clearance and volume of distribution in neonates and young children.

Authors:  A W Kelman; A H Thomson; B Whiting; S M Bryson; D A Steedman; G E Mawer; L A Samba-Donga
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more
  15 in total

1.  Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis.

Authors:  S H Kang; M R Poynton; K M Kim; H Lee; D H Kim; S H Lee; K S Bae; O Linares; S E Kern; G J Noh
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

Review 2.  Artificial neural network as a novel method to optimize pharmaceutical formulations.

Authors:  K Takayama; M Fujikawa; T Nagai
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

3.  Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks.

Authors:  J Opara; S Primozic; P Cvelbar
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

4.  Use of artificial neural networks to predict drug dissolution profiles and evaluation of network performance using similarity factor.

Authors:  K K Peh; C P Lim; S S Quek; K H Khoh
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

5.  Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates.

Authors:  I S Nestorov; S T Hadjitodorov; I Petrov; M Rowland
Journal:  AAPS PharmSci       Date:  1999

Review 6.  The backpropagation neural network--a Bayesian classifier. Introduction and applicability to pharmacokinetics.

Authors:  R J Erb
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 7.  Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

Authors:  M M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.

Authors:  Sam H Haidar; Steven B Johnson; Michael J Fossler; Ajaz S Hussain
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

9.  From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks and Genetic Programming.

Authors:  Aleksander Mendyk; Sinan Güres; Renata Jachowicz; Jakub Szlęk; Sebastian Polak; Barbara Wiśniowska; Peter Kleinebudde
Journal:  Comput Math Methods Med       Date:  2015-05-26       Impact factor: 2.238

10.  Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks.

Authors:  Aleksander Mendyk; Paweł K Tuszyński; Sebastian Polak; Renata Jachowicz
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.